Rocket Pharmaceuticals (RCKT) Return on Capital Employed (2015 - 2026)
Rocket Pharmaceuticals (RCKT) reported Return on Capital Employed of 76.15% for Q1 2026, down 1793.0% on a YoY basis from 4.5% in Q1 2025, and down 4.84% sequentially from 72.64% in Q4 2025.
Rocket Pharmaceuticals (RCKT) Return on Capital Employed (2015 - 2026) Analysis & Trends
Rocket Pharmaceuticals (RCKT) has 11 years of Return on Capital Employed data on file, last reported at 76.15% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 1793.0% year-over-year to 76.15%; the trailing twelve-month figure through Mar 2026 stood at 76.15% (down 1793.0% YoY), and the FY2025 full-year result was 58.1%, down 414.0% from the prior year.
- Return on Capital Employed retreated to 76.15% in Q1 2026, from 72.64% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 829.35% in Q3 2023 to a low of 110.26% in Q4 2023.
- A 5-year average of 177.75% and a median of 65.05% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed surged 41732 bps in 2022 and plunged 90139 bps in 2024, its largest moves.
- Tracing RCKT's Return on Capital Employed over 5 years: stood at 94.42% in 2022, then declined by 17 bps to 110.26% in 2023, then jumped by 41 bps to 65.05% in 2024, then retreated by 12 bps to 72.64% in 2025, then declined by 5 bps to 76.15% in 2026.
- Business Quant data shows RCKT's Return on Capital Employed at 76.15% in Q1 2026, 72.64% in Q4 2025, and 68.94% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Rocket Pharmaceuticals | 357.93 Mn | 357.93 Mn | - | -76.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -76.15% |
| Dec 31, 2025 | -72.64% |
| Sep 30, 2025 | -68.94% |
| Jun 30, 2025 | -66.48% |
| Mar 31, 2025 | -58.23% |
| Dec 31, 2024 | -65.05% |
| Sep 30, 2024 | -72.04% |
| Jun 30, 2024 | -61.97% |
| Mar 31, 2024 | -52.97% |
| Dec 31, 2023 | -110.26% |
| Sep 30, 2023 | 829.35% |
| Jun 30, 2023 | 787.78% |
| Mar 31, 2023 | -99.34% |
| Dec 31, 2022 | -94.42% |
| Sep 30, 2022 | 685.78% |
| Jun 30, 2022 | 819.77% |
| Mar 31, 2022 | 797.58% |
| Dec 31, 2021 | 787.54% |
| Sep 30, 2021 | 784.26% |
| Jun 30, 2021 | 654.69% |